Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
Russo
Ethan B
EB
D000284:Administration, Oral; D000339:Affect / Q000187:drug effects; D001066:Appetite / Q000187:drug effects; D002185:Cannabidiol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002186:Cannabinoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002188:Cannabis; D017326:Clinical Trials, Phase III as Topic; D004311:Double-Blind Method; D013759:Dronabinol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy*; D009128:Muscle Spasticity / Q000188:drug therapy / Q000209:etiology; D009437:Neuralgia / Q000188:drug therapy; D010936:Plant Extracts / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012021:Reflex, Abnormal / Q000187:drug effects; D012449:Safety; D012890:Sleep / Q000187:drug effects; D013557:Switzerland; D016896:Treatment Outcome; D006113:United Kingdom
D002186:Cannabinoids; D010936:Plant Extracts; D002185:Cannabidiol; D013759:Dronabinol